DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/v4z6w3/cinv_existing_and) has announced the addition of the "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering.
The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. However, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020.
North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013.
The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview
Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million)
Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)
Chapter 6 Competitive Landscape
Chapter 7 Company Profiles
- GlaxoSmithKline plc
- Helsinn Holding S.A.
- Heron Therapeutics, Inc.
- Merck & Co., Inc.
- Tesaro, Inc.
For more information visit http://www.researchandmarkets.com/research/v4z6w3/cinv_existing_and